Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jun;21(6):659-61.
doi: 10.1634/theoncologist.2016-0074. Epub 2016 Apr 28.

Systemic Therapy for Invasive Bladder Cancer: The Value Proposition

Derek Raghavan  1
Affiliations
Comment

Systemic Therapy for Invasive Bladder Cancer: The Value Proposition

Derek Raghavan. Oncologist. 2016 Jun.

Abstract

Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy followed by definitive local treatment should be the treatment of choice for otherwise healthy and robust patients with T2b–T4 invasive bladder cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Comment on

References

    1. Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis. The Oncologist. 2016;21:708–715. - PMC - PubMed
    1. Raghavan D, Pearson B, Coorey G, et al. Intravenous cis-platinum for invasive bladder cancer. Safety and feasibility of a new approach. Med J Aust. 1984;140:276–278. - PubMed
    1. Raghavan D, Pearson B, Duval P, et al. Initial intravenous cis-platinum therapy: Improved management for invasive high risk bladder cancer? J Urol. 1985;133:399–402. - PubMed
    1. International Collaboration of Trialists Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomized controlled trial. Lancet. 1999;354:533–540. - PubMed
    1. Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171–2177. - PMC - PubMed